Apellis Pharmaceuticals (APLS) Competitors $24.26 +1.31 (+5.71%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$24.06 -0.21 (-0.85%) As of 08/4/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLS vs. VRNA, BBIO, BPMC, LEGN, ROIV, RGC, ELAN, RVMD, GRFS, and TGTXShould you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Roivant Sciences (ROIV), Regencell Bioscience (RGC), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Apellis Pharmaceuticals vs. Its Competitors Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Legend Biotech Roivant Sciences Regencell Bioscience Elanco Animal Health Revolution Medicines Grifols TG Therapeutics Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) and Apellis Pharmaceuticals (NASDAQ:APLS) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk. Which has better earnings and valuation, VRNA or APLS? Verona Pharma PLC American Depositary Share has higher earnings, but lower revenue than Apellis Pharmaceuticals. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerona Pharma PLC American Depositary Share$42.28M212.36-$173.42M-$2.00-52.74Apellis Pharmaceuticals$781.37M3.92-$197.88M-$1.82-13.33 Do analysts recommend VRNA or APLS? Verona Pharma PLC American Depositary Share presently has a consensus price target of $109.00, indicating a potential upside of 3.35%. Apellis Pharmaceuticals has a consensus price target of $36.83, indicating a potential upside of 51.83%. Given Apellis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verona Pharma PLC American Depositary Share 0 Sell rating(s) 11 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.15Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.60 Which has more risk & volatility, VRNA or APLS? Verona Pharma PLC American Depositary Share has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Do institutionals and insiders believe in VRNA or APLS? 85.9% of Verona Pharma PLC American Depositary Share shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 4.8% of Verona Pharma PLC American Depositary Share shares are held by insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is VRNA or APLS more profitable? Verona Pharma PLC American Depositary Share has a net margin of 0.00% compared to Apellis Pharmaceuticals' net margin of -30.24%. Verona Pharma PLC American Depositary Share's return on equity of -69.65% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Verona Pharma PLC American Depositary ShareN/A -69.65% -28.00% Apellis Pharmaceuticals -30.24%-116.09%-26.72% Does the media favor VRNA or APLS? In the previous week, Apellis Pharmaceuticals had 30 more articles in the media than Verona Pharma PLC American Depositary Share. MarketBeat recorded 42 mentions for Apellis Pharmaceuticals and 12 mentions for Verona Pharma PLC American Depositary Share. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.24 beat Apellis Pharmaceuticals' score of 0.80 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verona Pharma PLC American Depositary Share 9 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apellis Pharmaceuticals 13 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive SummaryApellis Pharmaceuticals beats Verona Pharma PLC American Depositary Share on 12 of the 17 factors compared between the two stocks. Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLS vs. The Competition Export to ExcelMetricApellis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.90B$3.02B$5.51B$9.35BDividend YieldN/A2.46%4.74%4.15%P/E Ratio-13.3318.0629.1424.41Price / Sales3.92272.71435.00101.03Price / CashN/A40.5624.4827.20Price / Book13.188.628.525.77Net Income-$197.88M-$54.98M$3.24B$264.99M7 Day Performance28.02%-0.87%0.65%-0.68%1 Month Performance34.89%16.08%7.97%7.08%1 Year Performance-28.42%14.18%30.98%23.80% Apellis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLSApellis Pharmaceuticals4.7075 of 5 stars$24.26+5.7%$36.83+51.8%-33.6%$2.90B$781.37M-13.33770Earnings ReportAnalyst UpgradeAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share2.012 of 5 stars$105.09-0.2%$109.00+3.7%+401.8%$8.96B$42.28M0.0030Positive NewsUpcoming EarningsBBIOBridgeBio Pharma4.7689 of 5 stars$46.23-0.2%$61.50+33.0%+82.4%$8.79B$221.90M0.00400BPMCBlueprint Medicines0.7055 of 5 stars$129.46flat$128.25-0.9%N/A$8.36B$562.12M-52.41640Upcoming EarningsLEGNLegend Biotech3.712 of 5 stars$41.51-4.3%$73.33+76.7%-29.7%$7.97B$627.24M0.002,609News CoveragePositive NewsUpcoming EarningsROIVRoivant Sciences2.2301 of 5 stars$11.35-1.7%$16.50+45.4%+9.5%$7.85B$29.05M0.00860Upcoming EarningsRGCRegencell Bioscience0.0422 of 5 stars$13.80-8.3%N/AN/A$7.44BN/A0.0010ELANElanco Animal Health3.9116 of 5 stars$14.59-2.2%$16.17+10.8%+14.1%$7.41B$4.44B15.879,000Positive NewsUpcoming EarningsRVMDRevolution Medicines4.4956 of 5 stars$37.26-1.7%$68.91+84.9%-15.5%$7.06B$11.58M0.00250Positive NewsUpcoming EarningsGRFSGrifols3.258 of 5 stars$10.09-0.1%$10.30+2.1%+41.4%$6.94B$7.81B0.0023,822Dividend AnnouncementTGTXTG Therapeutics4.1374 of 5 stars$35.99-2.5%$43.80+21.7%+55.2%$5.86B$329M153.75290News CoverageEarnings ReportOptions VolumeGap Down Related Companies and Tools Related Companies VRNA Alternatives BBIO Alternatives BPMC Alternatives LEGN Alternatives ROIV Alternatives RGC Alternatives ELAN Alternatives RVMD Alternatives GRFS Alternatives TGTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLS) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APLS Stock Alerts